JPRN-UMIN000026436
Completed
未知
Investigation for advanced cancer patients' treatment preferences and their end of life care - Investigation for advanced cancer patients' treatment preferences and their end of life care
agoya City University0 sites400 target enrollmentApril 1, 2017
Conditionsadvanced cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- advanced cancer
- Sponsor
- agoya City University
- Enrollment
- 400
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. physically too ill to complete the questionnaire 2\. severe mental disorders 3\. severe cognitive disorders 4\. judged by the treating physician to be unsuitable to participate
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A study for people with advanced colorectal cancer who have been treated with a specific chemotherapy regimen (Bevacizumab, Oxaliplatin, and a Fluoropyrimidine) which was ineffective in stopping the spread of the colorectal cancer. Study participants will receive a different chemotherapy regimen (Irinotecan, Folinic Acid, and 5-Fluorouracil) and be randomly and unknowingly assigned to also receive the study drug (ramucirimab) or a non-active compound (placebo).Metastatic Colorectal CancerMedDRA version: 17.0Level: LLTClassification code 10010036Term: Colorectal carcinomaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2010-021037-32-DEEli Lilly and Company Limited, Indianapolis1,050
Terminated
Phase 1
A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AMLAdvanced CancerSolid TumorsAcute Myeloid Leukemia RefractoryAcute Myeloid Leukemia, in RelapseNCT03690154Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.67
Terminated
Not Applicable
Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid TumorsCancerAdult Solid TumorLymphomaMultiple MyelomaNCT03061305Strata Oncology58,213
Completed
Not Applicable
Colomid: Midkine as a predictive marker in colorectal cancerACTRN12613000111774Calvary Mater Newcastle Hospital33
Terminated
Phase 1
A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced CancerMetastatic Melanoma and Other Solid TumorsNCT04809805Bayer5